Wahren-Herlenius M, Dörner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382(9894):819–831

Article  CAS  PubMed  Google Scholar 

Wang L et al (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369–395

Article  CAS  PubMed  Google Scholar 

Harroud A, Hafler DA (2023) Common genetic factors among autoimmune diseases. Science 380(6644):485–490

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller FW (2023) The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol 80:102266

Article  CAS  PubMed  Google Scholar 

Castillo-Fernandez JE et al (2014) Epigenetics of discordant monozygotic twins: implications for disease. Genome Med 6(7):60

Article  PubMed  PubMed Central  Google Scholar 

Waddington CH (2012) The epigenotype. 1942. Int J Epidemiol 41(1):10–3

Article  CAS  PubMed  Google Scholar 

Skvortsova K et al (2018) Functions and mechanisms of epigenetic inheritance in animals. Nat Rev Mol Cell Biol 19(12):774–790

Article  CAS  PubMed  Google Scholar 

Orsolic I et al (2023) Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet 39(1):74–88

Article  CAS  PubMed  Google Scholar 

Dai W et al (2024) Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther 9(1):332

Article  PubMed  PubMed Central  Google Scholar 

Davalos V, Esteller M (2023) Cancer epigenetics in clinical practice. CA Cancer J Clin 73(4):376–424

PubMed  Google Scholar 

Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27

Article  CAS  PubMed  Google Scholar 

Mor F (2007) Treatment of autoimmune disease: time for a paradigm shift? Arch Immunol Ther Exp (Warsz) 55(1):13–18

Article  CAS  PubMed  Google Scholar 

Bakshi J et al (2018) Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allergy Immunol 55(3):352–367

Article  PubMed  PubMed Central  Google Scholar 

Seibel MJ et al (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1(1):59–70

Article  CAS  PubMed  Google Scholar 

Danieli MG et al (2024) Exposome: epigenetics and autoimmune diseases. Autoimmun Rev 23(6):103584

Article  CAS  PubMed  Google Scholar 

Egger G et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457–463

Article  CAS  PubMed  Google Scholar 

Peedicayil J (2016) Epigenetic drugs for multiple sclerosis. Curr Neuropharmacol 14(1):3–9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szyf M (2010) Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol 39(1):62–77

Article  CAS  PubMed  Google Scholar 

Kaminskas E et al (2005) FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3):176–182

Article  CAS  PubMed  Google Scholar 

Pleyer L et al (2014) Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 93(11):1825–38

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei AH et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383(26):2526–2537

Article  CAS  PubMed  Google Scholar 

Gore SD et al (2006) Decitabine Nat Rev Drug Discov 5(11):891–892

Article  CAS  PubMed  Google Scholar 

Nieto M et al (2016) The European Medicines Agency review of decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Oncologist 21(6):692–700

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhillon S (2020) Decitabine/Cedazuridine: first approval. Drugs 80(13):1373–1378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mann BS et al (2007) FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247–1252

Article  CAS  PubMed  Google Scholar 

Piekarz RL et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor Romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410–5417

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poole RM (2014) Belinostat: first global approval. Drugs 74(13):1543–1554

Article  CAS  PubMed  Google Scholar 

Shi Y et al (2015) Results from a multicenter, open-label, pivotal phase II study of Chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766–1771

Article  CAS  PubMed  Google Scholar 

San-Miguel JF et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195–1206

Article  CAS  PubMed  Google Scholar 

Kim ES (2017) Enasidenib: first global approval. Drugs 77(15):1705–1711

Article  CAS  PubMed  Google Scholar 

DiNardo CD et al (2018) Durable remissions with Ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med 378(25):2386–2398

Article  CAS  PubMed  Google Scholar 

Hoy SM (2020) Tazemetostat: first approval. Drugs 80(5):513–521

Article  PubMed  Google Scholar 

Morschhauser F et al (2020) Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21(11):1433–1442